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INTRODUCTION 
 
 Overlap syndrome is defined in a patient when a combination of more than one 
major feature of connective tissue disease is present with a specific serological test
1
. The 
common symptoms of overlap syndrome include sclerodactyly, arthritis and Raynaud’s 
phenomenon. A distinguishable feature in patients with autoimmune disease is the 
presence of non organ specific auto antibodies to RNA, DNA and to proteins that bind 
them.  For MCTD the well known serological marker is anti U1RNP antibody. 
 
 The ribonuclear proteins are auto antigens located on small nuclear RNP 
particles. They are uridine rich. The major action is splicing of pre messenger RNA. Anti 
U1RNP is associated with features of scleroderma, including Raynaud’s phenomenon. 
There has been a close association of anti U1RNP antibody with pulmonary fibrosis and 
negative correlation with renal involvement. 
 
 MCTD, although an overlap syndrome, does not have any distinctive clinical 
feature. The components of MCTD (systemic sclerosis, systemic lupus erythematosus 
and idiopathic inflammatory myositis) do not occur simultaneously but consecutively 
over years. Raynaud’s phenomenon occurs in almost all patients with MCTD. 
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AIM OF THE STUDY 
 
1) To correlate anti U1RNP antibody with the clinical spectrum of Mixed connective 
tissue disease (according to Kasukawa’s criteria) and Overlap Syndrome.   
2) To analyse the association of anti U1RNP antibody with the pulmonary 
manifestations among Mixed connective tissue disease and Overlap Syndrome.  
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REVIEW OF LITERATURE 
 
 We find that patients diagnosed as autoimmune rheumatic disease were not 
classified with ease into one of the well defined clinical syndromes such as systemic 
lupus erythematosus, systemic sclerosis or idiopathic inflammatory myositis. The issue is 
complicated by such diseases with a tendency to overlap with one another which results 
in continuous manifestations of clinical features among rheumatic diseases. Now, there is 
an increased awareness in diagnosing such patients as ‘Overlap Syndrome’. In literature, 
any of the combinations of rheumatic diseases has been reported. The very purpose of 
identifying Overlap Syndrome is useful in prognostication and facilitating disease 
management. 
 
 Autoimmune diseases are heterogenous and the role of auto antibodies in the 
immuno pathogenesis of disease process is not certain. As a normal physiological 
process auto antibodies are formed but when in excess become injurious to self. These 
auto antibodies act either directly against a particular tissue or by the formation of 
immune complexes. 
 
AUTOIMMUNITY IN OVERLAP SYNDROME WITH REFERENCE TO U1RNP 
 
 To process pre messenger RNA to mature RNA, spliceosomes are needed
2
. 
Spliceosomes are made up of 300 different proteins and 5 RNAs. Their different parts 
are targets of immunogenecity in several auto immune connective tissue diseases.  By 
increasing the post translational modification in spliceosomal components, as occurring 
during apoptosis, the immunogenic potential is heightened
3
. The major antigenic 
determinants of spliceosomal components are small nuclear ribonuclear protein (snRNP) 
and heterogenous nuclear RNP (hnRNP)
4
. 
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 Small RNAs in the range of 80-350 nucleotides combined with proteins 
constitute small nuclear ribo nuclear protein. There is a high quantity of uridine in these 
RNAs. Hence these are called as U-RNAs. Researchers, by immuno precipitating these 
U-RNAs were able to identify five different types namely U1, U2, U4, U5 and U6
5
. The 
protein components of these complexes are the target antigens to auto antibodies. The 
back bone of U1-RNP is double stranded U1-RNA molecule. 
 
 Non specific proteins and specific proteins constitute U1-RNP complex. The 
specific proteins with their corresponding molecular weights include U1-A’ (33,000), 
U1-C (22,000) and U1-70K (68,000)
6
. In SLE the main target antigen is Sm protein
7
 and 
the clinical features unique to MCTD ares correlated with 70kD specificity with an 
immuno dominant epitope embracing amino acid residue at positions 119-126. 
 
 The hnRNPs contain pre-mRNA and structurally related proteins with molecular 
weight ranging between 33 to 43 kD. There are nine hnRNP core proteins that have been 
identified and they include A1, A2, B1a, B1b, B1c, B2, C1, C2 and C3
8
. Anti –RA33 
against 33-kD hnRNP-A2 is present in nearly a third of patients with rheumatoid 
arthritis, systemic lupus erythematosus and mixed connective tissue disease
9
. There have 
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been associations of anti RA33 with erosive arthritis in lupus, systemic sclerosis and 
mixed connective tissue disease
10
. This antibody also foretells the onset of RA in patients 
with very early polyarthritis
11
. 
 
 Uniquely there is no correlation of anti-RA33 in polymyositis or overlap of 
PM/DM or PM/Scl. The hnRNP-A2 has antigenic epitopes that contain two RNA 
binding sites, one at the N-terminal region and the other at the glycine rich C-terminal 
end. The significance of these sites is that, certain rheumatic diseases target the two 
binding sites differently. RA and SLE sera selectively target the second RNA binding 
site and MCTD sera reacts with both RNA binding domains
12
. 
 
GENERATION OF AUTOIMMUNITY (U1RNP) 
 Spliceosomes may be the target antigen for auto antibody but the autoimmune 
response will result against the entire particle by antigen presenting cells. Hence all the 
components of the spliceosomal complex will be subjected to antigen processing and 
finally presented to HLA class type 2. HLA molecule polymorphism will result in 
diversified antibody response to recruit other antigens also and this is called as ‘epitope 
spreading’. This process is important in the pathogenesis of auto immune connective 
tissue disorders
13
. As a result of epitope spreading, the immune pathogenesis and auto 
antibody response becomes altered with time and this correlates well with the change in 
the clinical scenario
14
. 
 
 The role played among the proteins presented by HLA and the T cell receptors 
are crucial in the development of autoimmune reaction. HLA DR4 and DR2 are linked 
with 70kD and anti-U1-RNP antibodies
15
. The presence of DR2 and DR4 have a 
common set of peptide acids at positions 26, 28, 30, 31, 32, 70 and 73 in beta position for 
binding of antigen
16
. The most commonly found sequence of the polypeptide 70kD, 
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having different epitopes is KDK DRD RKR RSS RSR
17
. This site is the preferred target 
of mixed connective tissue disease but not by the systemic lupus erythematosus sera
18
. 
Varying degrees of epitope spreading characterize the different types of auto immune 
connective tissue disorders. SLE and MCTD patients have antibodies to both snRNP and 
hnRNP but MCTD patients have more restricted anti spliceosomal antibody 
representation. RA sera have anti spliceosomal antibodies only against hnRNP
19
. 
Conserved molecules also act as source of auto antigens against which auto antibodies 
form. The mechanism of these auto antigen formation is postulated by two theories 
namely apoptotic modification
20
 and molecular mimicry
21
. 
 
 To overcome the tolerance to self antigens the peptides get altered during 
apoptosis and then presented to the immune system. The self antigens are crowded onto 
the blebs on the surface of apoptotic cells. Broken down pieces of endoplasmic 
reticulum, ribonuclear protein Ro and ribosomes are contained in the smaller blebs. The 
apoptotic bodies which form the larger blebs encompass snRNP, Ro, La and 
nucleosomal DNA
17
. Many enzymes are up regulated which result in post translational 
changes in the breakdown of proteins. These alterations include transglutamination, 
citrullination, dephosphorylation, phosphorylation and finally the linkage to ubiquitin, 
makes the molecule more antigenic. Caspase 3
22
 acts on the U1-70K and converts it into 
a C-terminal fragment and this contains the major epitope B cell, which is targeted by the 
antibodies. 
 
 Anti U1-RNP antibodies may form as a result of molecular mimicry. 
Recognizing non self protein is the first step of auto antibody formation. There has been 
increased apoptosis under certain situations like toxins, drugs, infections and ultra violet 
radiation. Antigens that closely resemble U1-RNP produce cross reactive antibodies. The 
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extraneous antigens get cleared with time but the endogenous antigenecity of U1-RNP 
persists. Some evidence does exist for the hypothesis of molecular mimicry in connective 
tissue diseases but still needs further evaluation. 
 
 Multiple other antibodies have been identified in patients with MCTD and they 
include anti-Ro/SS-A, antiphospholipid, anti-hn-RNP-A2 and antibodies against other 
components of U1-RNP complexes. The reason for the development of other antibody 
specificity is not known and epitope spreading may play a role. The role of U1-RNP in 
the pathogenesis of MCTD is not known although it is needed for the diagnosis of the 
disease. 
OVERLAP SYNDROME 
Overlap of systemic sclerosis and myositis 
 There has never been a uniform spectrum identified in patients with systemic 
sclerosis/ myositis overlap. Systemic sclerosis patients have pronounced overlap features 
with other connective tissue disorders. Myositis/Systemic Sclerosis Overlap Syndrome 
occurs as frequently as the tRNA synthetase syndrome. Many of these patients do not 
present with prominent skin changes (sine scleroderma) or have only a limited form of 
the disease. Muscle weakness may occur either concurrently, before the onset or after the 
establishment of systemic sclerosis. 
 
 The foremost clinical manifestation of systemic sclerosis overlap cases is the 
presence of Raynaud’s phenomenon and it should be differentiated from primary 
Raynaud’s. The effect on the gastrointestinal tract is more prevalent in SSc/Myositis 
overlap. Pneumatosis intestinalis and pseudo-obstruction as complications of the 
syndrome were recorded to be severe
23
.    
 
 HLA-DR3 is found to be positive in more than 90% of patients with systemic 
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sclerosis and myositis overlap; however the frequency of this HLA is not common in 
Japanese population as in North American and European population. The genetic impact 
of the disease is suggested by the high frequency of HLA DQA *0501
24
. These genetic 
influences alone are not the sole cause of the disease as multiple independent factors 
contribute to the pathogenesis of the disease. 
 
 The presence of anti nucleolar antibody, which is usually done by indirect 
immunofluroscence gives an idea to the presence of Myositis/ Systemic Sclerosis 
overlap. By using the double immunodiffusion technique and indirect 
immunofluorescence, this antibody was first reported. A homogenous nucleolar pattern 
with poor staining of nucleoplasm is produced by Pm/Scl antibodies. The exact function 
of Pm/Scl antigen is not known, although it has some role in the maturation of 
ribosomes. This antigen is sited at the nucleolar granular component, the place where the 
assembly of ribosomes occur. Pm/Scl is a protein complex of around 16 different types 
of polypeptides with arrange of molecular weight of 20-110 kDa
25,26
. Auto-antibodies 
against two main molecules are 75kDa (Pm/Scl-75 protein) and 100kDa (Pm/Scl-100 
protein). Nucleolar macromolecular complex are the target antigens for these auto-
antibodies. These Pm/Scl auto-antibodies are seen in 6% of patients with 
dermatomyositis/polymyositis. In patients with systemic sclerosis alone it is found in 2% 
of individuals but in overlap syndrome of systemic sclerosis and myositis overlap, 
Pm/Scl auto-antibodies are identified in 24% of patients. Among individuals with these 
auto-antibodies, 43% to 88% have sclerodermatomyositis. The specific auto antibodies 
associated with this overlap are anti PM/Scl, anti-U2-RNP, anti-Ku and anti-U5snRNP
27
.  
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 In a study conducted in Japan, anti-Ku antibodies were associated with systemic 
sclerosis myositis overlap in 50% of patients. In these Japanese patients anti-Pm/Scl 
antibodies ware found to be very rare whereas anti-Ku antibodies were documented in 
only 10% of North American cases of scleromyositis
28
. The significance of the anti-
PM/Scl auto antibodies is the relatively benign course of the interstitial lung disease and 
the good response to corticosteroids. Furthermore there is no association of this 
autoantibody with malignancy. Joint symptoms had significant association with these 
anti bodies. There were no reported cases on the presence of anti-Jo-1 in systemic 
sclerosis myositis overlap. Anti –Ku antibodies had no correlation to malignancy in 
patients with PM/Scl syndrome, as is the case with idiopathic inflammatory myositis. In 
4% of these overlap patients, there is presence of antibodies to signal recognition particle 
(SRP) and they show poor prognosis. SRP in PM/Scl is recognized with distinctive 
necrosis of muscle fibers and the rapidity with which the muscle weakness occurs is very 
severe. 
 
 The treatment target in SSc/myositis overlap is the management of skin damage, 
muscle weakness and alveolitis. As high dose steroids may precipitate a renal crisis in 
patients with systemic sclerosis, high dose steroids should be used with caution for 
myositis component in systemic sclerosis myositis overlap
29
. The drugs commonly used 
include corticosteroids, cytotoxic drugs like azathioprine, methotrexate, mycophenolate 
mofetil, cyclophosphomide and certain biologicals. 
 
 The effective management of skin, joint and muscle weakness does not 
necessarily imply the good control of alveolitis of systemic sclerosis/myositis overlap. 
Methotrexate and anti-TNF alpha therapy is associated with high incidence of 
aggravating ILD in these cases
30
. Uncontrolled myositis responds to rituximab
31,32
 and 
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mycophenolate mofetil
33,34
 is found to be useful in improvement of skin and muscle 
features. Persistent and severe Raynaud’s may need the addition of prostaglandins and 
antagonists to endothelin receptors.    
 
MIXED CONNECTIVE TISSUE DISEASE (MCTD) 
 MCTD is another overlap syndrome, first identified by Sharp et al in 1971
35
. It 
consists of SLE, systemic sclerosis and polymyositis/dermatomyositis and with the 
association of U1-RNP antibodies. The recognition of mixed connective tissue disease is 
characterized by the presence of specific antibodies and the associated clinical features.   
 
 Nuclear antigenic pool that was soluble in normal saline, termed extractable 
nuclear antigen was used for complement fixation test, as the initial serologic test for 
MCTD. After the introduction of hemagglutination, where the antigenic mixture is 
treated by enzymatic action, ribonuclease (RNase) sensitive part of the antigen was 
identified as the target antigen for auto antibodies in mixed connective tissue disease. 
The differentiating factor between SLE and MCTD is that, auto antibodies in SLE 
reacted with RNase resistant fragment of the extractable nuclear antigen, whereas MCTD 
with that of RNase sensitive fragment
36
. By using immuno diffusion
37
 technique, RNase 
resistant component has been recognized as Sm antigen and RNase sensitive as RNP. 
Both Smith and RNP antigens are destroyed by trypsin, indicating the presence of 
protein in them. Immunoprecipitation studies showed that Sm and RNP had 
ribonucleoproteins in them. This was done using [
32
 P] labelled cells. 
 
Epidemiology and HLA of MCTD 
 The exact prevalence of mixed connective tissue disease is not known and may 
be approximately 10/100,000. This disease is more common in females, like any other 
connective tissue disease and the female to male ratio is 9:1. 80% -90% of MCTD occurs 
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in the third decade. The disorder has also been reported in children and in persons above 
80 years of age. No known environmental factor has been reported in the 
etiopathogenesis of the disease, except the exposure to the chemical agent vinyl 
chloride
38
. 
 
 HLA associated with MCTD is DR4. DR3 and DR5 have no associations, although 
they have been reported in SLE and systemic sclerosis respectively
39
. The presence of DR4, 
could give the link for the occurrence of joint erosions in these patients.   
 
Clinical features 
 The onset of clinical features in mixed connective tissue disease may be that of 
manifestations of a lupus, systemic sclerosis, polymyositis or rheumatoid arthritis. 
Raynaud’s phenomenon, inflammatory polyarthritis, sclerodactyly, swollen hands and 
gastro esophageal reflux symptoms are some of the most common clinical features of 
MCTD. Malar rash, hair fall, glandular enlargement and renal damage occur less 
frequently. Constitutional features like arthralgia, myalgia, fever and fatigue are also 
common in individuals with MCTD. 
 
Proposed classification criteria for MCTD 
 There are no single commonly accepted criteria for MCTD. Four different criteria 
are available at present for MCTD and they include Sharp, Alarcon-Segovia, Kahn and 
Kasukawa
40,41,42,43
. 
 
SHARP’s Criteria 
 This consists of 5 major and 11 minor criteria to differentiate among certain 
MCTD from probable MCTD. To diagnose probable MCTD anti U1RNP antibody is not 
essential, but its absolute presence is needed for establishing a definitive diagnosis.        
 12 
                 
 
 
ALARCON-SEGOVIA Criteria 
 This consists of five clinical criteria plus the presence of high titer anti-RNP 
antibodies.   
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KAHN’s Criteria 
                  This has 4 clinical criteria besides the need for the presence of high titer anti-
RNP antibodies. It almost mimics Alarcon-Segovia criteria.  
 
KASUKAWA’S Criteria 
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Joints and muscles 
 Patients with MCTD may present with minimal arthralgia to joint erosions. Small 
and large joint involvement, erosive arthritis and sometimes arthritis mutilans can 
occur
44
. In erosive joints, RF is found to be positive in nearly 70% of individuals
45
. 
Common arthritic symptom in MCTD is polyathralgia and it is also one of the early 
features, occurring in nearly 60% of patients. On clinical examination of the forearm, 
peritendinous nodules, usually small in size have been documented. 
 
 Muscular involvement has been reported in 80-90% of MCTD individuals. The 
pattern of muscle involvement is like any other connective tissue disease, with the 
proximal group of muscles being more commonly affected. Muscle enzyme analysis 
show elevated creatinine kinase and electromyography recording gives a picture of 
inflammatory myopathy. Usually the presentation of muscle weakness is acute, with or 
without fever. The onset can also be insidious. Some cases have persistent myopathy
46,47
. 
 
Skin manifestations 
 One of the most consistent skin manifestations of mixed connective tissue disease 
is Raynaud’s phenomenon. The percentage of occurrence of Raynaud’s varies between 
75-90% of patients with MCTD. This clinical feature may antedate other manifestations 
by months or even years. Vascular pathogenesis of middle sized arteries correlates with 
Raynaud’s phenomenon. Puffy hands and sausage digits occur in 70% of individuals 
with MCTD. The histopathological appearance of skin and nailfold capillaroscopy 
changes of digits simulates that of systemic sclerosis. Bushy appearance of capillaries in 
nailfold capillaroscopy is a distinct feature of mixed connective tissue disease
48
. Sicca 
symptoms, skin rash simulating dermatomyositis, oral ulcers and genital ulcers have 
been recorded. Urticarial vasculitis with low complements, were seen in patients, 
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although this presentation is not common. Features of SLE, like malar rash, 
photosensitivity and oral ulcers are also generally seen in these patients.    
 
Raynaud’s phenomenon 
 This phenomenon was initially identified by A.G.Maurice Raynaud, who was a 
physician in France. Raynaud’s phenomenon is further categorised into Raynaud’s 
disease and Raynaud’s syndrome. When there is no identifiable cause it is called as 
Raynaud’s disease and if it occurs, secondary to some other connective tissue disorder, 
this phenomenon is called as Raynaud’s syndrome.  
 
 Raynaud’s phenomenon usually occurs in young females and can be familial 
sometimes. It is shown that Raynaud’s syndrome may precede the onset of systemic 
disorder by even twenty years. 85% of individuals with MCTD have this syndrome. 
Regarding the pathogenesis of Raynaud’s phenomenon, the following theories are put 
forth and they include interaction between blood and blood vessel, neurogenic 
mechanism and role of inflammation.    Vascular endothelial cells function in regulating 
the blood flow by secreting many substances.  There is imbalance in the secretion of 
vasodilators like nitric oxide and prostacyclin (PGI2) and vasoconstrictors like endothelin 
-1, which causes constriction of the blood vessels, inflammatory state and a procoagulant 
vascular endothelium. The role of platelets in pathogenesis of Raynaud’s phenomenon 
has been studied and shows that platelets exhibit increased clumping. The platelets 
release thromboxane A2, growth factors like TGF-beta and PDGF.  
 
 Hyperexcitability of sympathetic neurons cause increased constriction of blood 
vessels as proposed by the neurogenic theory as one of the mechanism for Raynaud’s 
phenomenon. Role of estrogen and stress, causing vasoconstriction has been studied and 
reported in pathogenesis of this phenomenon. Macrophages, TNF, lymphotoxins and 
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proteins of T- cell origin play an important part in the immune response of Raynaud’s 
phenomenon. 
 
 The clinical findings of Raynaud’s include three phases and they are a phase of 
pallor, cyanosis followed by redness of fingers. These three phases of colour change do 
not typically present in all individuals but the stage of pallor must occur to make a 
diagnosis of Raynaud’s phenomenon. Emotional stress, elderly age group, female sex, 
frequent severe attacks, persistent vasospasm are some of the markers of progression of 
Raynaud’s phenomenon. Microscopic examination of the nail fold helps in determining 
the structural and functional changes of the circulation in the microvasculature system. 
Radioisotope clearance, thermography and Doppler flowmetry using laser technology are 
some of the methods to diagnose Raynaud’s phenomenon. 
 
 Calcium channel blockers have become the mainstay of medical management of 
Raynaud’s phenomenon. This acts through the vasodilatory mechanism but also has 
antithrombotic and antiplatelet effect. Other vasodilators like inositol nicotinate, 
prazosin, losartan
49
, phosphodiesterase inhibitors like sildenafil
50
 and endothelin 
blockers like bosentan
51
 have been tried in the medical treatment of Raynaud’s 
phenomenon. Prostaglandin analogues, iloprost infusion helps in patients with ulcers of 
the digits and painful ischemia
52
. This is found to be more helpful in healing ulcers than 
the calcium channel blockers. Alprostadil, PGE1 and PGE1 alpha, cyclodextrin were 
also used in Raynaud’s, in patients not tolerating iloprost. Oral prostaglandin analogues 
like cisaprost, oral iloprost and limaprost have been tried in patients with Raynaud’s 
phenomenon.                          
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Cardiovascular disease 
 The incidence of involvement of the heart ranges from 11% to 85% and this 
depends on the technique used and how the cardiac involvement was defined. The 
commonest cardiac presentation is pericarditis and it is usually mild
53
. Myocardial 
involvement, left ventricular diastolic dysfunction, conduction defects and mitral valve 
prolapse have been reported in patients by using echocardiography. Vasculopathy in the 
form of proliferation of the intima and hypertrophy of the media, affecting small and 
medium arteries, similar to systemic sclerosis is seen. Vitamin D level and 
cardiovascular disease have indirect relationship and vitamin D level has been found to 
be low in patients with mixed connective tissue disease
54
. 
 
Lung manifestations 
 In 85% of individuals with mixed connective tissue disease, lung abnormalities 
are made out. Varied lung features have been described including pulmonary 
hypertension, interstitial lung disease and fibrosis. The common causes of mortality in 
these patients include pulmonary arterial hypertension, congestive cardiac failure and 
infections. Individuals with mixed connective tissue disease and PAH have a higher rate 
of pericardial effusions, although good hemodynamic and right ventricular echo findings 
were made out compared to other connective tissue diseases, by REVEAL (registry to 
evaluate early and long term pulmonary arterial hypertension disease management) 
study. Natriuretic peptide B type was found to be elevated in MCTD patients and DLCO 
was decreased. Breathlessness and chest pain, usually pleuritic are the common features 
made out clinically. Effusions and thickening of the pleura, lung infiltrates and 
interstitial changes are reported by radiographic examination. Rare cases of pulmonary 
haemorrhage and acute onset interstitial pneumonia have been documented
55,56,57
. 
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INTERSTITIAL LUNG DISEASE (ILD) 
 Interstitial lung disease is a group of heterogenous parenchymal lung diseases 
that have some common clinical features, pathological and radiological features. ILD can 
be symptom free and diagnosed by high resolution computerised tomogram of the chest 
and lung function tests. Interstitial lung disease can be divided into idiopathic interstitial 
pneumonia and diffuse parenchymal lung disease. Idiopathic pulmonary fibrosis is one 
of the types of the first subset and connective tissue diseases causing ILD constitute the 
second type. The commonest connective tissue disease associated with ILD is systemic 
sclerosis. Other diseases like mixed connective tissue disease, undifferentiated 
connective tissue disease, rheumatoid arthritis, Sjogren’s syndrome, idiopathic 
inflammatory myositis-namely polymyositis/dermatomyositis and systemic lupus 
erythematosus also cause interstitial lung disease, although to a lesser extent.  
 
 The incidence of ILD in mixed connective tissue depends on the selection of 
patients and the method used for diagnosing the lung disorder. The prevalence of 
interstitial lung disease is found to be higher than that was previously reported. Nearly 
66% of patients with ILD in MCTD have decreased diffusing capacity for carbon 
monoxide. The main lung function abnormality is of a restrictive pattern and about 50% 
of patients have this problem
58
. On high resolution computed tomography, the prominent 
radiological changes noted were ground glass opacity with thickening of the septa. 
Histological pattern is that of non specific interstitial pneumonia. These changes were 
predominant in the lower lobes. This feature simulates systemic sclerosis-ILD picture.  
 
 Based on the histological type and radiological pattern, the different types of 
interstitial lung disease include non specific interstitial pneumonia (NSIP), usual 
interstitial pneumonia (UIP), diffuse alveolar damage, acute interstitial pneumonia, 
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cryptogenic organising pneumonia, desquamative interstitial pneumonia and 
lymphocytic interstitial pneumonia.     
 
Pathogenesis of ILD 
 The exact mechanism of lung fibrosis is not known but endothelial and epithelial 
damage predate lung inflammation and the end result is fibrosis. There is contribution 
from inflammatory cytokines, vascular endothelial injury and autoimmunity in the 
pathogenesis of interstitial pulmonary involvement. Profibrotic and proinflammatory 
mediators have a role in the immunopathogenesis and they include growth factors, 
cytokines, lipids and prostanoids. There is strong evidence for the role of transforming 
growth factor beta, endothelin-1 and the platelet derived growth factors. Hence targeting 
the profibrotic cytokines is an important area of research for better therapeutic 
management. 
 
TGF beta response mediators 
Canonical Smad signalling 
 The main function of this signalling pathway is the phosphorylation of the type 1 
transforming growth factor beta receptors. Phosphorylation is of the sequential nature 
and the activin-like kinase-5 of TGF receptors are exclusively involved. Apart from this, 
Smad proteins, intracellular signalling elements are also phosphorylated. Activated TGF 
beta, bind to the receptor and send signals to the Smad proteins in the cytoplasm, through 
phophorylation. These signals are then transmitted to the nucleus of the cell and then 
genetic transcription begins, whereby collagen type 1, fibronectin, actin and connective 
tissue growth factors are generated. All these play an important role in the fibrosis of 
lung parenchyma
59
. Blocking the phosphorylation of Smad proteins and signals of TGF 
beta are future targets in the management of fibrosis. 
 20 
 
c-Abelson tyrosine kinase 
 c-Abelson tyrosine kinase is a member of the Src family of tyrosine kinases. This 
gets activated by transforming growth factor beta
60
. In 95% of patients with chronic 
myeloid leukemia, mutations of c-Abl have been documented. This is indeed responsible 
for increased proliferation of myeloid cell lineage. The role of c-Abl in non myeloid cells 
has demonstrated that inhibiting the kinase activity of c-Abl in vitro, abolished the 
genetic expression of collagen stimulation. In vivo studies of animal models showed the 
prevention of fibrosis of skin and lung. Imatinib mesylate is found to be the c-Abl 
inhibitor. It blocked the synthesis of collagen and transformation of myofibroblast 
induced by transforming growth factor beta.  
 
Egr-1 
 Egr-1 is a transcription element that is produced at the site of injury. Egr-1 is 
responsible for cell survival, differentiation and proliferation of cells and plays an 
important role in the acute phase of response of tissues to injury
61
. In lung the abnormal 
expression of Egr-1, was well correlated with the progression of fibrosis of lung
62
. It is 
one of the main elements of activation of fibroblast in lung which is induced by binding 
protein of insulin like growth factor. By inhibiting the expression of Egr-1 or blocking 
the activity by imatinib mesylate, the ongoing fibrosis can be controlled. 
 
Peroxisome Proliferator-Activated Receptor Gamma  
(PPAR Gamma) 
 Peroxisome proliferator-activated receptor gamma is a transcription factor and a 
receptor in the nucleus. Initially this was identified only in adipocytes but recently 
described in many tissues. The predominant role played by PPAR gamma is 
adipogenesis, but it has roles in immunity and inflammation. One of the newer functions 
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that has been indentified for PPAR gamma is the anti-fibrotic activity. Activated PPAR 
gamma inhibited the transforming growth factor beta response in skin and fibroblasts of 
lung
63
. Studies show that PPAR gamma is decreased in the biopsy tissues taken from 
lungs of patients with interstitial lung disease
64
. Prostaglandins and fatty acids act as 
natural agonists of PPAR gamma. Synthetic drugs like rosiglitazone, was found to 
decrease the skin fibrosis caused by bleomycin and also inflammation in vivo. Apart 
from this, it also inhibits collagen synthesis induced by transforming growth factor beta, 
differentiation of myofibroblasts and cellular migration among fibroblasts. 
 
Endothelin-1 
 Endothelin-1 is an effective constrictor of blood vessels that is secreted by the 
cells of the endothelium, mesenchymal cells and epithelial cells. It has two receptors 
namely, endothelin-1A and endothelin-1B. Production of matrix is increased and 
fibroblasts are pooled in at the site of injury, by endothelin-1
65
. It also triggers the 
secretion of transforming growth factor beta in the fibroblasts of lung tissues. Research 
on the utility of bosentan, antagonist of endothelin-1, for the management of idiopathic 
pulmonary fibrosis and systemic sclerosis associated interstitial lung disease is going on. 
 
Chemokines and growth factors 
Lysophosphatidic Acid 
 Platelets and fibroblasts are activated and they produce lysophosphatidic acid. It 
is a phospholipid that is active biologically, and induces various effects in tissues 
subjected to injury. Recent studies show that lysophosphatidic acid has a role in the 
pathogenesis of idiopathic pulmonary fibrosis
66
. The recruitment of fibroblasts during the 
fibrosis of lungs is mediated by the lysophosphatidic acid, by binding to the receptor 
LPA1. The receptor LPA1 is found on epithelial, endothelial cells and fibroblasts. The 
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futuristic approach would be in blocking the pathway of LPA-LPA1, for patients with 
systemic sclerosis associated with lung fibrosis. 
 
Insulin like Growth Factor 
 In systemic sclerosis related lung fibrosis, the role of insulin like growth factor 
and their proteins have been identified. In BAL study and in serum of patients with 
interstitial lung disease, the level of insulin like growth factor-1 is found to be elevated
68
. 
In animal models of lung fibrosis, by blocking IGF pathway, there was resolution of 
fibrosis. 
 
Connective tissue growth factor 
 It is a matricellular element that is rich in cysteine. Connective tissue growth 
factor plays an important role in the synthesis of connective tissue and formation of new 
blood vessels. It helps in the synthesis of extracellular matrix, differentiation of 
myofibroblasts and mediates transforming growth factor beta
69
. In patients with systemic 
sclerosis, lungs and skin show increased levels of connective tissue growth factors. 
Monoclonal antibodies are prepared against these growth factors, which would be a 
therapeutic target for patients with lung fibrosis.                                                                                             
 
PULMONARY HYPERTENSION 
 Pulmonary hypertension may be asymptomatic or present with respiratory or 
cardiac failure. When the mean arterial pressure of the pulmonary vasculature is more 
than 25mmHg it is defined as pulmonary hypertension. This reference value is valid 
when the patient is at rest and measured by catheterising the right side of the heart
70
. In 
this setting of pulmonary arterial hypertension, the capillary wedge pressure of the 
pulmonary vasculature should be less than 15mmHg. Right heart catheterisation, apart 
from identifying hemodynamic abnormalities also helps in discriminating arterial 
 23 
hypertension from venous hypertension due to occlusive venous disease and left heart 
failure. 
 
 Symptoms of pulmonary arterial hypertension include breathlessness on exertion, 
fatigability, syncopal attacks or precordial pain. In early stages of pulmonary 
hypertension the clinical examination may be normal, but later stages show a tricuspid 
regurgitation murmur, loud pulmonary sound and features of right heart failure. Patients 
can die suddenly due to hypoxia and congestive cardiac failure. 
 
 Doppler echocardiography is used to diagnose suspected pulmonary 
hypertension. Pulmonary arterial pressure is estimated by this modality of investigation. 
Ventricular dysfunction, atrial enlargements, valvular disease, intra cardiac shunt and 
pericardial effusion are identified by Doppler echocardiography. The sensitivity of this 
imaging modality to evaluate pulmonary arterial pressure is 79-100%
71
. 
 
Diffusing capacity for carbon monoxide 
 A decrease in diffusing capacity for carbon monoxide in the absence of restrictive 
or obstructive lung disease indicate an error in the exchange of gases secondary to 
pulmonary arterial hypertension. The fall in DLCO may progress for years before the 
establishment of pulmonary arterial hypertension. 
 
Pro BNP 
 The presence of pulmonary arterial hypertension and right heart strain can be 
diagnosed by increased levels of serum pro brain natriuretic peptide
72
. Even moderate 
elevation (>395 pg/ml) of pro brain natriuretic peptide (N terminal) may help in 
diagnosing pulmonary hypertension. 
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6 minutes walk test 
 It is an exercise testing to assess cardio pulmonary system. This can give us the 
baseline functional idea for assessing therapeutic response. 6 minutes walk test cannot 
precisely estimate the severity of pulmonary arterial hypertension.                                                                                                                  
 
Gastrointestinal disease 
 The incidence of gastrointestinal manifestations in mixed connective tissue 
disease is around 66% to 74%
73
.  This feature may be a prominent clinical finding, in the 
setting of overlap with systemic sclerosis. Among the gastrointestinal presentations, 
dysfunction of esophagus is more common. This symptom may not manifest clinically at 
the onset and the commonest symptom is dysphagia. Gastrointestinal reflux symptoms 
and dysmotility of esophagus occur at increased frequency in individuals with features 
related to systemic sclerosis than to systemic lupus erythematosus. Esophageal 
manometry study revealed that MCTD patients have comparatively less severe 
abnormality than that of systemic sclerosis
74
. The manometric abnormality did not 
correlate with skin disorder. There was decrease in the sphincter pressure of esophagus 
and also the reduction in the peak of peristalsis in the lower end of esophagus. Rarely, 
the sphincter pressure in the upper esophagus was also noted to be reduced. Patients with 
mixed connective tissue disease can also present as acute abdomen due to mesenteric 
vasculitis, acute pancreatitis, hemoperitoneum or colonic perforation.  Diarrhoea, protein 
losing enteropathy and chronic active hepatitis are some of the other gastrointestinal 
manifestations
75-78
. The features of gastrointestinal system correlate well with the 
duration of disease course. 
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Renal manifestations 
 One of the important complications of mixed connective tissue disease is the 
involvement of the kidneys. Usually the kidneys are involved in an asymptomatic 
manner and the frequency of presentation is found to be 25%
79
. U1RNP antibodies 
protect against the development of proliferative glomerulonephritis
80
. Rarely the kidneys 
are affected severely. Common types of renal involvement include membranous 
glomerulonephritis and mesangial glomerulonephritis. Proliferative glomerulonephritis 
both focal and diffuse can be present although rare. There are case reports of immune 
complex mediated nephritis in some studies. Vascular and interstitial involvement of the 
kidneys is not common in mixed connective tissue disease patients as seen with systemic 
sclerosis. Children with MCTD have higher a rate of nephritis compared to that of adult 
counterparts. Decreased levels of complements are seen in these patients indicating a 
higher rate of glomerulonephritis, which includes membranous lesions as well. Children 
with mixed connective tissue disease are more frequently subjected for renal biopsy, 
because of the increased incidence of sub clinical nephritis in them
81
. Histological 
findings similar to renal crisis of scleroderma may be seen sometimes in MCTD patients.  
The other renal features include accelerated hypertension, acute kidney injury and 
microangiopathic haemolytic anemia
82
. 
 
Haematological manifestations 
 The common haematological findings in mixed connective tissue disease patients 
are decrease in total leucocytes count, anaemia of chronic disease, increased in gamma 
globulin levels and positivity for Coomb’s test but without the evidence for haemolysis83. 
Nearly 75% of individuals have anemia but with lower grade. Lymphopenia relating to 
the activity of the disease is commonly reported. Less frequent haematological 
presentations include decrease in platelet count, aplastic red cells and thrombotic 
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thrombocytopenic purpura. None of the haematological features are specific for mixed 
connective tissue disease, although decreased leucocyte count and anaemia have 
correlation with the activity of the disease course and show improvement to treatment 
when other clinical manifestations are treated. 
 
Neurological manifestations 
 Central and peripheral nervous system manifestations are less common in 
patients with mixed connective tissue disease compared to other clinical features. Recent 
studies indicate that the neurological involvement in MCTD individuals is higher than 
that reported earlier. The commonest neurological presentation is trigerminal neuralgia 
and this may be one of the early features of clinically undiagnosed mixed connective 
tissue disease
84,85
. Headaches usually due to vascular involvement and peripheral 
neuropathy of the same cause have been reported
86,87
. Patients with MCTD can present 
with aseptic meningitis as one of the features of central nervous system. The 
cerebrospinal fluid analysis of these patients shows higher concentration of interferon 
gamma and interleukin -6. The level of anti U1RNP antibodies in cerebrospinal fluid is 
found to be increased compared to serum and correlate with the activity of the disease 
process
88
. Anti U1RNP antibodies are found in both serum and cerebrospinal fluid 
analysis of patients with neuropsychiatric symptoms of MCTD and systemic lupus 
erythematosus. These anti U1RNP antibodies serve as markers of central 
neuropsychiatric features in individuals with the antibodies. The production of the anti 
U1RNP antibodies intrathecally is prominent in patients who have features of 
neuropsychiatric symptoms. The other rare neurological manifestations are intracranial 
bleed, vasculitis of the retinal vessels, optic neuropathy, transverse myelitis and cauda 
equina syndrome
89-93
. 
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Auto antibodies 
 Rheumatoid factor is found to be positive in nearly 50-70% of individuals with 
mixed connective tissue diseases
94
. The percentage of positivity for anti citrullinated 
peptide antibody in mixed connective tissue disease is aroud 50%. The other antibodies 
that have reported are nucleosomes, fibrillin-1 and heterogenous nuclear 
ribonuleoprotein-A2. The frequency with which the antibodies to phospholipid occur is 
less common compared to systemic lupus erythematosus and their presence is related to 
hypertension of the pulmonary vasculature and decreased platelets
95,96
. No association 
has been linked either with abortions or thrombosis. The prevalence of antibodies against 
beta 2 glycoprotein is not common in mixed connective tissue disease and their clinical 
significance is the association with pulmonary hypertension. In nearly 50% of patients 
with MCTD, antibodies to endothelial cells are seen and they are linked to the 
development of vascular injuries of kidneys and lungs.    
 
Pregnancy 
 The effect of mixed connective tissue disease on pregnancy and the foetus is 
conflicting. There are studies which document nearly 40% increase in flare of disease 
during antenatal period and also higher incidence of loss of foetus
97
.  The reason for 
complications during pregnancy is thought to be due to autoimmunity against the tissues 
of placenta. On immunostaining the basement membrane of trophoblast, 
immunoglobulins like IgA, IgM and IgG, complements and fibrinogen are shown to be 
deposited. Spontaneously occurring abortions in mixed connective tissue disease have 
been related to the presence of anti endothelial antibodies
98
. Children born with lower 
birth weight are common among patients with severe Raynaud’s and this correlation has 
been documented in individuals with mixed connective tissue diseases. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
 Prospective cross sectional study 
 
DURATION OF STUDY 
 January 2012-December 2013 
 
ETHICAL COMMITTEE APPROVAL 
 Obtained before starting the study 
 
CONSENT 
 Informed consent for all patients in their own language obtained                         
 
SELECTION OF STUDY SUBJECTS 
 All patients with features of suspected overlap syndrome and mixed connective 
tissue disease (according to Kasukawa’s criteria) attending the Department of 
Rheumatology, Rajiv Gandhi Government General Hospital, were enrolled. 
 
NUMBER OF STUDY CASES 
 43 patients 
  
METHODOLOGY 
 All patients who satisfied the inclusion criteria were chosen and a detailed history 
was obtained and complete clinical examination was done. All the enrolled patients were 
subjected to laboratory investigations (haemogram, biochemical parameters and urine 
routine), Electrocardiogram, Echocardiography, Ultrasonogram, Upper 
gastrointestinalscopy and Immunological investigations (C-reactive protein, Rheumatoid 
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factor, anti nuclear antibody and ANA profile 3). Chest x-ray, high resolution 
computerised tomogram of the chest and pulmonary function tests were done to asses 
pulmonary involvement of the cases under study. 
 
 ANA profile 3 was done using Immunoblot method.  
 
INCLUSION CRITERIA 
 Patients with clinical features suggestive of overlap syndrome (systemic lupus 
erythematosus, systemic sclerosis and myositis) and mixed connective tissue disease 
were included. 
 
EXCLUSION CRITERIA 
1) Patients with well defined isolated connective tissue diseases like  
Rheumatoid arthritis, Systemic lupus erythematosus, Systemic sclerosis, 
Idiopathic inflammatory myositis, Sjogren’s syndrome. 
 
2) Children below 16 yrs.    
 
STATISTICAL METHODS 
 Descriptive statistical analysis has been carried out in the present study. Results 
on continuous measurements are presented on Mean SD and results on categorical 
measurements are presented in percentage. Chi-square test has been used to find the 
significance of study parameters on categorical scale between two groups. All analyses 
were two tailed and p<0.05 was considered significant. SPSS version 16.0 was used for 
data analysis. 
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ANA ELISA 
Principle: 
 In the ANA screen ELISA kit, purified nuclear antigens are being coated on to 
wells of micro titre plate. If  IgG type of ANA specific antibody is present it binds to the 
antigen. Washing is done to remove all the unbound materials. If any antigen antibody 
complex is there, it binds to the added enzyme conjugate. Again washing is done to 
remove excess enzyme conjugate and then substrate is added. On incubation of the plate 
there is hydrolysis of the substrate by the enzyme.  
Test procedure: 
 Universal precautions are followed during the procedure. All the reagents are 
dispensed in the centre of the well and the tip of the pipette should not touch 
the wall of the micro well. 
 Prepare work sheet and remove the kit from the refrigerator and leave it at 
room temperature for 30 minutes. 
Sample: 
 Use only serum as specimen for the test 
Preparation of wash buffer: 
 Check the buffer concentrates for the presence of salt crystals. 
           50ml of buffer is prepared for each strip 
 Mix 20ml 25x wash buffer concentrate with 480 ml of distilled water 
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Procedure: 
 Samples to be brought to room temperature 
 Samples arranged so that well A1 is negative control and well B1 is positive 
control and well C1 & D1 is calibrator. 
 To 200 µl of sample diluents, 10 µl of test sample is added to make a 1:21 
dilution and mixed nicely. 
 Dispense 100 V of diluted sera in E1 well & other diluted samples in their 
appropriate wells. Tap the holder to remove air bubbles from the liquid and 
mix well gently and cover with a seal. 
 At room temperature incubation  is done for 20 minutes   
 The seal is removed and wash buffer of 300 µl is used to wash the wells 
thrice.  
 An absorbent paper is used for blotting. 
 In each well enzyme conjugate of 100 µl is added. 
 The plate is sealed with a cover and is incubated for 20 minutes at room 
temperature. 
 The seal is removed and wash buffer of 300 µl is used to wash the wells 
thrice.  
 An absorbent paper is used for blotting. 
 Dispense 100 µl of TMB substrate and incubate for 10 minutes at room 
temperature. 
 Add 100 µl of stop solution. 
 Read at 450 nm using ELISA reader 
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 ANA – INDIRECT IMMUNOFLUORESCENCE (Hep-2)  
Principle: 
The antibodies present in the sample bind the relevant antigens. Once bound, the antigen-
antibody complex is shown with an antibody conjugated with fluorescein and is 
visualized under a fluorescent microscope. 
Test procedure: 
 To keep the slides at room temperature for 30 minutes before performing the 
assay. 
 The phosphate buffer saline is prepared before performing the assay. 
 According to the slide to be used, prepare a screening dilution. 
 
Reagents 1/10 dilution 1/40 dilution 
PBS  buffer 450 µl 300 µl 
Serum 50 µl 100 µl 
 
 With diluted samples and diluted controls the reactive areas are covered. 
 Incubation is done at room temperature for a period of 30 minutes. Perform a 
quick wash with PBS. 
 Three washings should be performed of 5 minutes each, putting the slides in the 
coplin jar containing PBS, shaking softly. 
 Take the slides off the PBS, shake the excess on absorbent paper and keep the 
reactive areas wet. 
 Diluted Anti IgG FITC is used to cover the reactive areas immediately and kept 
for incubation at room temperature in a moist chamber for 30 minutes. 
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 Steps for washing to be repeated. 
 Cover the reactive areas with Evan’s blue. 
 Wash the excess stain with PBS, keeping the reactive areas wet. 
 Put the mounting medium immediately on the cover slide. 
 Results are interpreted based on the pattern and the intensity of fluorescence in 
1/40 dilution. Positive reaction in 1/10 dilution but negative in 1/40 dilution is 
reported as negative. 
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ANA profile 3 
Procedure: 
 
To take the strip provided by the manufacturer and place it on the tray. 
 
 
To add 10 µl serum sample to 100 µl diluents (30 minutes Incubation) 
 
 
Thrice washed with 1.5 ml wash buffer (incubate for 5min / wash) 
 
 
Add 100 µl conjugate (30 minutes Incubation) 
 
 
Thrice washed with 1.5 ml wash buffer (incubate for 5 min / wash) 
 
 
Add 100 µl substrate (10 minutes Incubation) 
 
 
 
Wash with 1.5 ml distilled water 
 
 
Add 100 µl stop solution (5 minutes Incubation) 
 
 
Read results 
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RESULTS AND ANALYSIS 
Table 1: AGE DISTRIBUTION 
S.NO 
AGE 
(IN YEARS) 
NUMBER OF PATIENTS 
1 17-29 18 
2 30-39 18 
3 40-49 7 
 
 
Figure 1: AGE DISTRIBUTION 
 
 
Most number of patients are between second and third decade. 
 
 
 
 
 
  
42% 
42% 
16% 
NO.PATIENT 
17-29 YRS 30-39 YRS 40-49 YRS
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Table 2: SEX DISTRIBUTION 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Male 2 4.7 4.7 4.7 
Female 41 95.3 953 100.0 
Total 43 100.0 100.0  
 
  
Figure 2: SEX DISTRIBUTION 
 
 
 
 Proportion of females with overlap syndrome/mixed connective tissue disease 
was higher and the ratio of females to males was 20.3:1. 
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Table 3: U1RNP 
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Positive 34 79.1 79.1 79.1 
Negative 9 20.9 20.9 100.0 
Total 43 100.0 100.0  
 
 
 
Figure 3: U1RNP 
 
 
 
 
Percentage of anti U1RNP antibody positivity was 79.1% and 20.9% of patients 
were found to be negative for anti U1RNP.    
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U1RNP 
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Figure 4: SPECTRUM OF OVERLAP DISEASES 
 
 
 
Mixed connective tissue disease  - 58.14% (n=25) 
Systemic sclerosis/myositis           - 25.58% (n=11) 
Systemic sclerosis/SLE                  - 11.66% (n=5) 
SLE/myositis                                  - 4.66% (n=2)  
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Figure 5: ANTI U1RNP ANTIBODY STATUS AMONG 
OVERLAP SYNDROME AND MCTD 
 
50% of patients with Overlap Syndrome are positive for anti U1RNP antibody 
 
 
Figure 6: PULMONARY MANIFESTATIONS AMONG OVERLAP 
SYNDROME AND MCTD 
 
ILD is more common among MCTD patients compared to Overlap syndrome. The prevalence of 
PHT is almost equal in both the groups. 
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                        Figure 7:CLINICAL FEATURES OF MCTD PATIENTS 
 
Raynaud’s phenomenon, the commonest and renal involvement, the least common manifestation 
in MCTD patients.   
Figure 8:CLINICAL FEATURES OF OVERLAP SYNDROME 
CORRELATING WITH ANTI U1RNP ANTIBODY   STATUS 
 
Arthritis is the commonest feature and renal manifestations scored the least, among 
Overlap Syndrome group. 
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Figure 9: CLINICAL MANIFESTATIONS OF PATIENTS WITH OVERLAP 
SYNDROME and MIXED CONNECTIVE TISSUE DISEASE. 
 
 
 
Table 4:  P Value of Clinical Features correlating with  
anti U1RNP antibody 
 
S.NO CLINICAL FEATURES P VALUE 
1. Puffy hands .12 
2. Arthritis .27 
3. Raynaud’s .02 
4. Renal .52 
5. PHT .41 
6. ILD .06 
7. Sclerodactyly .06 
8. Myositis .45 
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Table 5: U1RNP – ARTHRITIS 
   
            ARTHRITIS 
Total 
Positive Negative 
U1RNP 
Positive 
Count 31 3 34 
% within U1RNP 91.2% 8.8% 100.0% 
Negative 
Count 7 2 9 
% within U1RNP 77.8% 22.2% 100.0% 
Total 
Count 38 5 43 
% within U1RNP 88.4% 11.6% 100.0% 
 
Figure 10: U1RNP – ARTHRITIS 
 
 
 Proportion of  arthritis is higher in anti U1RNP positive group compared to anti 
U1RNP negative group (91.2% Vs 77.8%) though statistically insignificant (p 
value>0.05). 
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Table 6: U1RNP – RAYNAUD’S 
  
   
Raynaud’s 
Total 
Positive Negative 
U1RNP 
Positive 
Count 29 5 34 
% within U1RNP 85.3% 14.7% 100.0% 
Negative 
Count 4 5 9 
% within U1RNP 44.4% 55.6% 100.0% 
Total 
Count 33 10 43 
% within U1RNP 76.7% 23.3% 100.0% 
 
Figure 11: U1RNP – RAYNAUD’S 
 
 
 
 Proportion of Raynaud’s phenomenon positivity is higher in anti U1RNP 
antibody positive group compared to anti U1RNP antibody negative group (85.3% Vs 
44.4%) and had statistical significance with p value <0.05. 
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Table 7: U1RNP - ILD 
 
   
ILD 
Total 
Positive Negative 
U1RNP 
Positive 
Count 20 14 34 
% within U1RNP 58.8% 41.2% 100.0% 
Negative 
Count 2 7 9 
% within U1RNP 22.2% 77.8% 100.0% 
Total 
Count 22 21 43 
% within U1RNP 51.2% 48.8% 100.0% 
 
 
Figure 12: U1RNP - ILD 
 
 
  
 Proportion of interstitial lung disease is higher in anti U1RNP antibody positive 
group compared to anti U1RNP antibody negative group (58.8% Vs 22.2%) although 
statistically not significant (p value >0.05).  
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Table 8: U1RNP – PUFFY HANDS 
 
 
   
PUFFY HANDS 
Total 
Positive Negative 
U1RNP 
Positive 
Count 25 9 34 
% within U1RNP 73.5% 26.4% 100.0% 
Negative 
Count 4 5 9 
% within U1RNP 44.4% 55.6% 100.0% 
Total 
Count 23 20 43 
% within U1RNP 67.4% 32.6% 100.0% 
 
 
Figure 13: U1RNP – PUFFY HANDS 
 
 
 
 Proportion of patients with puffy hands is higher in anti U1RNP positivity 
compared to anti U1RNP negativity (73.5% Vs 44.4%) although statistically not 
significant (p value>0.05).  
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Table 9: U1RNP – RENAL 
   
RENAL 
Total 
Positive Negative 
U1RNP 
Positive 
Count 2 32 34 
% within U1RNP 5.9% 94.1% 100.0% 
Negative 
Count 1 8 9 
% within U1RNP 11.1% 88.9% 100.0% 
Total 
Count 3 40 43 
% within U1RNP 7.0% 93.0% 100.0% 
 
Figure 14: U1RNP – RENAL 
 
 
 
 Proportion of individuals without renal involvement is higher in anti U1RNP 
antibody positive group compared to U1RNP negative group (32 patients Vs 8 patients).    
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Table 10: U1RNP – SCLERODACTYLY 
 
 
   
SCLERODACTYLY 
Total 
Positive Negative 
U1RNP 
Positive 
Count 24 10 34 
% within U1RNP 70.6% 29.4% 100.0% 
Negative 
Count 3 6 9 
% within U1RNP 33.3% 66.7% 100.0% 
Total 
Count 27 16 43 
% within U1RNP 62.8% 37.2% 100.0% 
 
Figure 15: U1RNP – SCLERODACTYLY 
 
 
 Proportion of patients with sclerodactyly was higher in anti U1RNP antibody 
positive group compared to the negative group, though statistically not significant  
(p value>0.05) 
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Table 11:U1RNP – MYOSITIS 
 
 
   
MYOSITIS 
Total 
Positive Negative 
U1RNP 
Positive 
Count 22 12 34 
% within U1RNP 64.7% 35.3% 100.0% 
Negative 
Count 4 5 9 
% within U1RNP 44.4% 55.6% 100.0% 
Total 
Count 26 17 43 
% within U1RNP 60.5% 39.5% 100.0% 
 
Figure 16: U1RNP – MYOSITIS 
 
 
 Anti U1RNP antibody positivity had no statistically significant association with 
myositis (p value >0.05).  
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Table 12: U1RNP – PHT 
 
 
   
PHT 
Total 
Positive Negative 
U1RNP 
Positive 
Count 11 23 34 
% within U1RNP 32.4% 67.6% 100.0% 
Negative 
Count 1 8 9 
% within U1RNP 11.1% 88.9% 100.0% 
Total 
Count 12 31 43 
% within U1RNP 27.9% 72.1% 100.0% 
 
 
Figure 17: U1RNP – PHT 
 
 
 There is no statistically significant association between anti U1RNP antibody 
positivity and pulmonary hypertension. 
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Table 13: Chi-Square Test – Raynaud’s Phenomenon 
 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
P value 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 6.654
a
 1 .010   
Continuity Correction
b
 4.562 1 .033   
Likelihood Ratio 5.882 1 .015   
Fisher's Exact Test    .020 .020 
Linear-by-Linear 
Association 
6.499 1 .011   
N of Valid Cases
b
 43     
 
Statistically significant association was found (p value<0.05) between Raynaud’s 
phenomenon and anti U1RNP antibody.  
 
Table 14: Chi-Square Test - Renal 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
P value 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .300
a
 1 .584   
Continuity Correction
b
 .000 1 1.000   
Likelihood Ratio .269 1 .604   
Fisher's Exact Test    .515 .515 
Linear-by-Linear 
Association 
.293 1 .588   
N of Valid Cases
b
 43     
 
There is no positive correlation between renal involvement and anti U1RNP antibody  
(p value>0.05)  
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DISCUSSION 
 
 Our study is a cross sectional analysis, to find out the correlation between anti 
U1RNP antibody with various clinical manifestations of overlap syndrome and mixed 
connective tissue diseases. 
 
 This study selected mixed connective tissue disease patients according to 
Kasukawa’s criteria and the reason for choosing is that, this criterion does not exclude 
patients with Sm positivity or demand the need for the titre of U1RNP and the presence 
of U1RNP is sufficient enough for serological criterion. 
 The mean age of onset of disease in our study population is 32.16 years and the 
mean duration of disease is 27.79 months. 
            In our study of 43 cases, 25 cases were diagnosed to have MCTD and the rest as 
overlap syndrome. Of the 18 overlap syndrome patients, 9 were found to be positive for 
anti U1RNP antibody (not fulfilling the Kasukawa’s criteria for MCTD). 
            The foremost clinical feature of MCTD patients, in our analysis was Raynaud’s 
phenomenon and this was present in 96% of individuals. This correlated well with the 
study by Sharp et al
36, which points to the prevalence of Raynaud’s phenomenon to be 
around 75-90%.  88% of patients had arthritis and puffy hands, and these rank the second 
common manifestation among MCTD. Sclerodactyly was present in 80% and myositis in 
60% of patients with MCTD. The least identified feature was the renal involvement, 
occurring only in 8% of the cases. This coincides with the study by Lemmer et al
80
 on 
the renal involvement in MCTD patients. More than half (60%) the patients had ILD and 
only 32% of individuals with MCTD had PHT as right heart catheterisation was not 
done. 
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 Of the 18 overlap syndrome cases, arthritis was present in all the anti U1RNP 
antibody positive patients (100%). More than 2/3 of the patients with anti U1RNP 
antibody positivity (77.8%) presented with myositis and the study by Yoshihide Asano et 
al
99
 correlates with our finding. One patient without anti U1RNP antibody had focal 
segmental glomerulosclerosis on renal biopsy. None of the anti U1RNP antibody 
positive patients had renal involvement among overlap syndrome. About half the patients 
had Raynaud’s phenomenon (55%) and sclerodactyly (44%). Puffy hands were present 
in 1/3 (33%) of anti U1RNP antibody positive patients
99
. 7 patients (38.9%) of the 
overlap syndrome [5 patients (55.6%) with and 2 patients (22.2%) without anti U1RNP 
antibody] had ILD. 33.3% (anti U1RNP antibody positive) and 11.11% (anti U1RNP 
antibody negative) had PHT
99
.   
 In our study, we find that higher proportion of patients with anti U1RNP 
antibodies had joint involvement (91.2%), although statistically not significant  
(p value>0.05).  The presence of IgG anti 70kDa and IgM anti-B/B’ antibodies are 
largely associated with the presence of arthralgia/arthritis. This study correlated well 
with the reports of Ihn et al 1999
100
 and Lundberg et al 1992
101
 
 The prevalence of Raynaud’s phenomenon among our patients with anti U1RNP 
antibody positivity was higher compared to that of negative individuals (85.3% Vs 
44.4%) and statistically significant (p value<0.05). This correlated well with other 
international studies, like Spanish study by López-Longo FJ et al
102
, which links the 
association of U1RNP with Raynaud’s phenomenon due to anti 70kD-U1-RNP and 
 anti A U1RNP by immunoblotting.  
 Our study showed only two patients (5.9%) with anti U1RNP positivity to have 
renal involvement. Both had albuminuria and the spot urine protein creatinine ratio was 
less than 0.5, hence renal review at quarterly interval was advised and biopsy was not 
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done. We are aware of the fact that U1RNP antibodies are protective against the 
occurrence of diffuse proliferative glomerulonephritis
80
. Munves et al quotes in his study 
that patients with anti U1RNP antibodies have lower incidence of renal disease
103
. A 
study conducted by Migliorini et al in 2005
104
 Italy also states that U1RNP antibodies are 
associated with milder renal involvement. 
 There were a statistically significant number of patients with interstitial lung 
disease among U1RNP positive individuals (58.8% Vs 22.2%). The majority of pattern 
recognised was nonspecific interstitial pneumonia pattern. In 1992 Lundberg et al
100
 
found an association between the combination of presence of anti-A, anti-C, IgG-anti 70 
KDa and IgM-anti B/B’ antibodies with pulmonary fibrosis. In 1999, Ihn et al99 stated 
that patients with positive anti U1RNP had significantly more pulmonary fibrosis than in 
those who were negative (72% Vs 36% p value <0.01). Since HRCT chest was done in 
all patients, we were able to diagnose subclinical interstitial lung disease. 
 The prevalence of pulmonary hypertension among anti U1RNP positive 
antibodies, in our study was 32.4%. In a study conducted in Japan
105
, majority of 
pulmonary arterial hypertension-connective tissue disease group patients, suffered from 
mixed connective tissue disease or systemic lupus erythematosus with anti U1RNP 
antibodies. Anti U1RNP antibody was the most prevalent antibody (61%) in their study 
population. In a different study in Japan
106
, systemic sclerosis and mixed connective 
tissue disease had the largest prevalence of pulmonary arterial hypertension. Anti 
U1RNP antibody positivity and the presence of Raynaud’s phenomenon correlated with 
pulmonary arterial hypertension in that study. The true prevalence of PAH may not have 
been brought out in our analysis as PAH was diagnosed only by 3D echocardiography 
and right heart catheterisation was not done. 
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 Our analysis shows higher prevalence of sclerodactyly, puffy hands and myositis, 
although none had statistical significance. These findings have good correlation with the 
study by Lundberg et al
100
. The occurrence of puffy hands, sclerodactyly and myositis, 
were highly associated with the combined presence of anti-A, anti-C, IgG anti-70 kDa 
and IgM anti-B/B’ antibodies100.     
 Our centre, being a tertiary referral centre, there can be sampling bias, as patients 
may not be truly representative of the population at large. Therefore these results cannot 
be applied to the community in general.  
 The main drawback of our study is that it is a cross sectional study. It cannot 
define the cause effect relationship between U1RNP antibodies and the various clinical 
manifestations. Hence we need larger a cohort and a longer time period to establish the 
causal relationship between anti U1RNP antibodies and the varied clinical spectrum. 
 Although with its own limitations, we believe that our study will be a stepping 
stone for our future research on anti U1RNP antibodies among patients with overlap 
syndrome and mixed connective tissue disease on a larger scale.                       
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CONCLUSION 
 
 Mixed connective tissue disease and Overlap Syndrome is more common among 
females. 
 Second and third decades are the susceptible age group for MCTD and Overlap 
Syndrome. 
 Arthritis is the most prevalent symptom among the anti U1RNP antibody positive 
Overlap Syndrome group. 
 Raynaud’s phenomenon is the most common clinical feature of MCTD. 
 Statistically significant association was found between Raynaud’s phenomenon 
and anti U1RNP antibody positivity (p value <0.05). 
  Puffy hands, sclerodactyly and myositis are proportionately higher in anti 
U1RNP antibody positive group of MCTD and Overlap Syndrome (statistically 
not significant p value>0.05). 
  Interstitial lung disease is more common among anti U1RNP antibody positive 
patients in both MCTD and Overlap Syndrome (statistically not significant p 
value>0.05).  
 Renal manifestations are uncommon in both MCTD and Overlap Syndrome 
patients. 
 Renal involvement and PHT had no association with the presence of anti U1RNP 
antibody. 
DIGITAL PITTED SCAR 
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PROFORMA 
Name:    Age:   Sex:   Date: 
RCC No: 
Complaints:  
H/o. Present Illness: 
 
 
Past History: 
 
 
Personal History: 
 
Treatment History:  
 
Family History: 
 
GENERAL EXAMINATION 
Pallor:   Icterus    Cyanosis 
Clubbing:   Lymphadenopathy  Pedal Edema 
Raynaud’s Phenomenon 
Skin Thickening 
Swollen Hands 
Hair 
 
VITAL SIGNS 
Blood Pressure   Pulse Rate 
 
SYSTEM EXAMINATION 
Cardiovascular System  Respiratory System 
Abdomen     Central Nervous System 
Musculoskeletal System Examination 
INVESTIGATION 
Haemogram 
Hb:    TC:    DC 
Platelet:   ESR: 
Urine Routine 
Immunological 
CRP 
RF 
Anti-CCP 
ANA   ANA profile 3 IgG 
Biochemical 
Sugar:   Urea:    Creatinine: 
Bilirubin:    AST:    ALT: 
ALP:    Total Protein:  Albumin: 
Triglycerides:  Cholesterol:  LDL: 
HDL:    Uric Acid: 
Radiography 
CXR 
HRCT Chest 
USG Abdomen 
Miscellaneous  
PFT 
ECHO 
Referral 
Thoracic Medicine 
Cardiology 
Gastroenterology 
Neurology 
Nephrology 
S. NO AGE SEX DURATION JOINT
PUFFY 
HANDS
SCL FEVER
MALAR 
RASH
MYOSITIS RAYNAUD'S GERD PHT RENAL ILD U1RNP
1 23 F 2 MONTHS P P P P P N P P N N P P
2 27 F 6 MONTHS P P P P P P P P P N P P
3 27 F 7 YEARS P P P N N N P P N N N P
4 42 F 1 YEAR P P P N N P P P N N P P
5 20 F 2 YEARS P P P P P N P P N N P P
6 18 F 1 YEAR P P P P P N P P N N P P
7 42 F 10 YEARS P P P N N P P P P N N P
8 38 F 4 YEARS P P P P N P P N P N P P
9 48 F 2 YEARS P P N N N N P P N N P P
10 19 F 3 MONTH P P P N N N P P P N N P
11 35 F 8 MONTH P P N P N P P P N N N P
12 20 F 1 YEAR P P P P N N P N N N N P
13 40 F 8 MONTH N P N N N P P N N N P P
14 27 F 6 MONTHS P P N N N N P P P N P P
15 34 F 1 YEAR P P P P N P N P P N P P
16 27 F 1 YEAR P P P P N N P P N P P P
17 35 F 2 YRS P P P P P N P P N N N P
18 21 F 1 YEAR N P P P N P P P N N N P
19 40 F 10 YEARS P N P N N P P N P N N P
20 22 F 3 MONTH P P N P N N P P P p P P
21 17 F 1 YEAR P P P P N N P P N N N P
22 26 F 1 YEAR P P P P P N P P N N P P
23 38 F 3 MONTHS N P P P P P P P N N P P
24 27 M 5 MONTHS P N N P P P N N N N N N
25 40 F 3 MONTHS P N N N N P N P P N P P
26 49 F 3 YEARS P N P N N N N P N N P P
27 24 F 10 MONTHS P N N N P N N N N N P P
28 35 F 1 YEAR P P P P P N P P N N P N
29 36 F 6 MONTHS N P P P P N P N P N N N
30 35 F 2 YEARS P N P P N P N P N N P P
31 33 F 7 MONTHS P P N N P P P N N N N P
32 35 F 1 YEAR P N P P N P N P N N P P
33 44 M 7 YEARS P N N N N P P N N N N P
34 30 F 2 MONTHS P N N P N P P N P N N P
35 47 F 3 YEARS N N N N N P P P N N N N
36 22 F 6 MONTHS P P P P P P P P N N N N
37 42 F 7 MONTHS P N N N N P N N N N N N
38 20 F 2 YEARS P N N P N P N N N N N N
39 32 F 3 YEARS P N N N N P N N N P N N
40 44 F 2 YEARS P P N P N P N P N N P N
41 32 F 8 MONTHS P P P N N P P P N N N P
42 42 F 2 YEARS P P P N N P P P N N P P
43 28 F 10 MONTHS P N P N P N N P P N N P
P - Positive, N- Negative, SCL-Sclerodactyly, PHT- Pulmonary Arterial Hypertension, ILD- Interstitial Lung Disease, GERD- Gastro Esophageal Reflux Disorder
MASTER CHART
PATIENT CONSENT FORM 
Study Details: Clinical spectrum and pulmonary manifestations of 
patients with anti U1RNP antibody status 
Study Centre: Department of Rheumatology, 
Rajiv Gandhi Government General Hospital, 
Madras Medical College, Chennai-600 003. 
Patient may check () these boxes 
I confirm that I have read and understood the Information Sheet for 
the above study. I have- had the opportunity to ask questions and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time, without giving any reason, without my 
legal rights being affected. 
I understand that the Clinical study personnel, the Ethics Committee 
and the Regulatory Authorities will not need my permission to look at my 
health records both in respect to the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study. I 
agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results 
that arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and to faithfully co-operate with the 
study team, and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual 
symptoms. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
I hereby consent to participate in this study. 
 
Signature of Investigator Thumb Impression of Patient 
Patient Name/ Address 
Name of the Investigator 
Institution 
INFORMATION SHEET 
 We are conducting a study on “Clinical spectrum and 
pulmonary manifestations of patients with anti U1RNP 
antibody status” at Department of Rheumatology, Madras 
Medical College and Rajiv Gandhi Government General 
Hospital, Chennai-600003. 
 The privacy of the patients in the research will be 
maintained throughout the study. In the event of any 
publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to 
decide whether to participate in this study or to withdraw 
at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you 
at the end of the study period or during the study if 
anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of the Participant Signature of the Investigator 
Institution 
Date : 
MuhŒ¢á x¥òjš got«  
MuhŒ¢á jiy¥ò 
fy¥ò ïiz¥ò¤âR nehŒ 
MuhŒ¢á Ãiya« : Kl¡FthjÉaš Jiw, 
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id.  
g¤F bgWtÇ‹ bga® : 
ghÈd« : 
g¤FbgwgtÇ‹ v© : 
g§F bgWgt® ïjid () F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu¤fŸ vd¡F És¡f¥g£lJ . 
v‹Dila rªnjf¤fis nf£fî«, mj‰fhd jFªj És¡f¤fis bgwî« 
thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g¤nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹.  
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g¤FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis 
gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš 
ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid Koîfisí« 
k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® nk‰bfhŸS« MŒÉš 
ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g¤F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ ïªj MŒit nk‰bfhŸS« kU¤Jt 
mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ clš 
ey«ghâ¡f¥g£lhnyh mšyJ vâ®ghuhj tH¡fâ‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clnd mij kU¤J mÂÆl« bjÇÉ¥ng‹ vd cWâ 
mË¡»nw‹. 
ïªj MŒÉš vd¡F kU¤Jt gÇnrhjid, ïu¤j¥ gÇnrhjid 
brŒJbfhŸs eh‹ KG kdJl‹ r«kâ¡»nw‹.  
 
g¤nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g¤nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
MuhŒ¢á jftš jhŸ 
br‹id ïuhé›fhªâ muR bghJ kU¤Jtid Kl¡FthjÉaš 
Jiw¡F tU« nehahËfËl« fy¥ò ïiz¥ò¤âR nehŒ g‰¿a MuhŒ¢á.  
Ú¤fS« MuhŒ¢áÆš g¤nf‰f ÉU«ò»nwh«. ïªj MuhŒ¢áÆš 
fâ®å¢R á»¢ir mË¤J áy áw¥ò gÇnrhjid¡F c£gL¤â mj‹ 
jftšfis MuhŒnth«. mjdhš j¤fË‹ nehÆ‹ MŒt¿¡ifnah, 
á»¢irnah ghâ¥ò V‰glhJ v‹gij bjÇÉ¤J¡ bfhŸ»nwh«. 
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ 
MuhŒ¢áÆ‹ nghnjh j¤fsJ bgaiunah mšyJ milahs¤fisnah 
btËÆlkh£nlh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«.  
ïªj MuhŒ¢áÆš g¤nf‰gJ j¤fSila ÉU¥g¤â‹ ngÇš jh‹ 
ïU¡»wJ. nkY« Ú¤fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th¤fyh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj áw¥ò gÇnrhjidfË‹ Koîfisí« nehÆ‹ j‹ik g‰¿í« 
MuhŒ¢áÆ‹nghJ mšyJ MuhŒ¢áÆ‹ KoÉ‹ nghJ j¤fS¡F 
m¿É¥ngh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
 
 
-------------------------    ------------------------- 
MuhŒ¢áahs® ifbah¥g«   g¤nf‰ghs® ifbah¥g« 
njâ: 
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